Protocol summary
-
Study aim
-
The aim of this study is to determine the effects of selenium supplementation on gene expression involved in inflammation signaling pathway in patients with gestational diabetes.
-
Design
-
Study design: Parallel double-blind (both patients and researchers) randomized controlled clinical trial. Random assignment will be done by the use of computer-generated random numbers.
-
Settings and conduct
-
Population and sample size: 40 patients with gestational diabetes of eligible and referred to Kosar Clinic affiliated to Arak University of Medical Sciences, Arak, Iran in the study will be selected.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Patients with gestational diabetes and aged 18 to 40 years will be included in this study. Exclusion criteria: Taking selenium supplements before the intervention, needing insulin therapy, placenta abruption, pre-eclampsia, eclampsia, hypo and hyperthyroidism and Smokers
-
Intervention groups
-
Intervention: Patients will be assigned to receive either selenium (n=20) or placebo (n=20). Selenium and placebos capsules are similar in shape and size.
-
Main outcome variables
-
Outcomes: Gene expression involved in TNF-α (primary outcomes), and other inflammatory factors (secondry outcomes) signaling pathway will be quantified at study baseline and end-of-trial.
General information
-
Reason for update
-
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT201612045623N95
Registration date:
2016-12-04, 1395/09/14
Registration timing:
registered_while_recruiting
Last update:
2019-09-22, 1398/06/31
Update count:
1
-
Registration date
-
2016-12-04, 1395/09/14
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
Vice chancellor for research, Arak University of Medical Sciences
-
Expected recruitment start date
-
2016-11-15, 1395/08/25
-
Expected recruitment end date
-
2016-12-10, 1395/09/20
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Clinical trial of the effect of selenium supplementation compared with the placebo on gene expression involved in inflammation signaling pathway in patients with gestational diabetes
-
Public title
-
Effect of supplementation in treatment of patients with gestational diabetes
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Patients with gestational diabetes
aged 18 to 40 years
Exclusion criteria:
Taking selenium supplements before the intervention
Needing insulin therapy
Placenta abruption
Pre-eclampsia
Eclampsia
Hypo and hyperthyroidism
Smokers
-
Age
-
From 18 years old to 40 years old
-
Gender
-
Female
-
Phase
-
3
-
Groups that have been masked
-
- Participant
- Investigator
- Outcome assessor
-
Sample size
-
Target sample size:
40
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Randomization will be done by the use of computer-generated random numbers.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
Participants, investigators or the assessors of the outcomes are unaware of the study groups.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2016-11-14, 1395/08/24
-
Ethics committee reference number
-
IR.ARAKMU.REC.1395.308
Health conditions studied
1
-
Description of health condition studied
-
Gestational diabetes
-
ICD-10 code
-
E28.2
-
ICD-10 code description
-
Diabetes mellitus in pregnancy, unspecified
Primary outcomes
1
-
Description
-
TNF-α
-
Timepoint
-
At the beginning of the study and after 6 weeks of intervention
-
Method of measurement
-
PCR-RT
Secondary outcomes
1
-
Description
-
IL-1
-
Timepoint
-
At the beginning of the study and after 6 weeks of intervention
-
Method of measurement
-
PCR-RT
2
-
Description
-
IL-8
-
Timepoint
-
At the beginning of the study and after 6 weeks of intervention
-
Method of measurement
-
PCR-RT
3
-
Description
-
TGF-B
-
Timepoint
-
At the beginning of the study and after 6 weeks of intervention
-
Method of measurement
-
PCR-RT
4
-
Description
-
VEGF
-
Timepoint
-
At the beginning of the study and after 6 weeks of intervention
-
Method of measurement
-
PCR-RT
Intervention groups
1
-
Description
-
Intervention group: 200 µg selenium (Nature Made, California, USA), once a day, for 6 weeks orally.
-
Category
-
Treatment - Drugs
2
-
Description
-
Control group: Placebo (Barij Essence, Kashan, Iran), once a day, for 6 weeks orally.
-
Category
-
Treatment - Drugs
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Vice chancellor for research, Arak University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available